Joe E. Kiani, Chairman and CEO of Masimo, stated, "NAEMT recommendations specifically address the importance and necessity of screening for CO levels in the blood on the scene of an emergency, where appropriate recognition and management of CO poisoning can make a life-saving difference. We invented Masimo Rainbow SET Pulse CO-Oximetry to provide clinicians with a noninvasive way to quickly, easily and accurately measure CO levels in a patients' and rescuers' blood anywhere and anytime. The implication of our unique technology for the advancement of public safety initiatives worldwide by industry-leading organizations like NAEMT is an important step to eliminating unnecessary deaths and long-term health consequences associated with CO poisoning."
Masimo (Nasdaq: MASI) develops innovative monitoring technologies that
significantly improve patient care -- helping solve "unsolvable" problems.
In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse
oximetry, known as Masimo SET, and with it virtually eliminated false
alarms and increased pulse oximetry's ability to detect life-threatening
events. More than 100 independent and objective studies demonstrate that
Masimo SET provides the most trustworthy SpO2 and pulse rate measurements
even under the most difficult clinical conditions, including patient motion
and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow
SET, a breakthrough noninvasive blood constituent monitoring platform that
can measure many blood constituents that previously required invasive
procedures. Rainbow SET continuously and noninvasively measures
Copyright©2008 PR Newswire.
All rights reserved